Correlation Between Nuvectis Pharma and Mineralys Therapeutics,
Can any of the company-specific risk be diversified away by investing in both Nuvectis Pharma and Mineralys Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nuvectis Pharma and Mineralys Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Nuvectis Pharma and Mineralys Therapeutics, Common, you can compare the effects of market volatilities on Nuvectis Pharma and Mineralys Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nuvectis Pharma with a short position of Mineralys Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nuvectis Pharma and Mineralys Therapeutics,.
Diversification Opportunities for Nuvectis Pharma and Mineralys Therapeutics,
0.34 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Nuvectis and Mineralys is 0.34. Overlapping area represents the amount of risk that can be diversified away by holding Nuvectis Pharma and Mineralys Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mineralys Therapeutics, and Nuvectis Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nuvectis Pharma are associated (or correlated) with Mineralys Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mineralys Therapeutics, has no effect on the direction of Nuvectis Pharma i.e., Nuvectis Pharma and Mineralys Therapeutics, go up and down completely randomly.
Pair Corralation between Nuvectis Pharma and Mineralys Therapeutics,
Given the investment horizon of 90 days Nuvectis Pharma is expected to generate 1.28 times more return on investment than Mineralys Therapeutics,. However, Nuvectis Pharma is 1.28 times more volatile than Mineralys Therapeutics, Common. It trades about 0.01 of its potential returns per unit of risk. Mineralys Therapeutics, Common is currently generating about -0.01 per unit of risk. If you would invest 1,185 in Nuvectis Pharma on November 2, 2024 and sell it today you would lose (511.00) from holding Nuvectis Pharma or give up 43.12% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Nuvectis Pharma vs. Mineralys Therapeutics, Common
Performance |
| Timeline |
| Nuvectis Pharma |
| Mineralys Therapeutics, |
Nuvectis Pharma and Mineralys Therapeutics, Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Nuvectis Pharma and Mineralys Therapeutics,
The main advantage of trading using opposite Nuvectis Pharma and Mineralys Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nuvectis Pharma position performs unexpectedly, Mineralys Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mineralys Therapeutics, will offset losses from the drop in Mineralys Therapeutics,'s long position.| Nuvectis Pharma vs. Replimune Group | Nuvectis Pharma vs. Lyra Therapeutics | Nuvectis Pharma vs. Kronos Bio | Nuvectis Pharma vs. Gossamer Bio |
| Mineralys Therapeutics, vs. SEI Investments | Mineralys Therapeutics, vs. Carlyle Group | Mineralys Therapeutics, vs. Centessa Pharmaceuticals PLC | Mineralys Therapeutics, vs. Alto Neuroscience, |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Complementary Tools
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |